Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Cut to $136.00 by Analysts at Wells Fargo & Company

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective lowered by Wells Fargo & Company from $145.00 to $136.00 in a research note released on Friday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Other research analysts have also recently issued reports about the company. Oppenheimer cut Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 5th. Citigroup reissued an “outperform” rating on shares of Rhythm Pharmaceuticals in a research note on Friday, December 12th. Canaccord Genuity Group lifted their target price on Rhythm Pharmaceuticals from $114.00 to $141.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Morgan Stanley reissued an “overweight” rating and set a $150.00 price target on shares of Rhythm Pharmaceuticals in a research report on Thursday, December 11th. Finally, Zacks Research upgraded Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Rhythm Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $133.71.

Rhythm Pharmaceuticals Trading Down 5.7%

RYTM traded down $5.60 on Friday, hitting $92.47. The company had a trading volume of 313,298 shares, compared to its average volume of 650,791. The firm has a market cap of $6.17 billion, a P/E ratio of -29.95 and a beta of 2.00. The company’s fifty day moving average price is $104.28 and its 200 day moving average price is $103.50. Rhythm Pharmaceuticals has a 1 year low of $45.90 and a 1 year high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.06. The business had revenue of $57.25 million for the quarter, compared to the consensus estimate of $56.16 million. Rhythm Pharmaceuticals had a negative net margin of 110.32% and a negative return on equity of 433.21%. The business’s revenue was up 36.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.72) EPS. On average, analysts predict that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current year.

Insider Activity at Rhythm Pharmaceuticals

In related news, insider Pamela J. Cramer sold 3,350 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the sale, the insider owned 20,814 shares in the company, valued at $2,310,354. This trade represents a 13.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Hunter C. Smith sold 4,385 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the transaction, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at approximately $11,190,445.12. This trade represents a 3.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 25,003 shares of company stock valued at $2,589,015 in the last 90 days. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. RA Capital Management L.P. lifted its position in shares of Rhythm Pharmaceuticals by 17.3% in the fourth quarter. RA Capital Management L.P. now owns 6,666,837 shares of the company’s stock valued at $713,618,000 after acquiring an additional 985,478 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Rhythm Pharmaceuticals by 24.3% in the 4th quarter. Vanguard Group Inc. now owns 6,210,916 shares of the company’s stock valued at $664,816,000 after purchasing an additional 1,214,489 shares in the last quarter. State Street Corp boosted its stake in shares of Rhythm Pharmaceuticals by 8.4% during the 4th quarter. State Street Corp now owns 2,198,615 shares of the company’s stock worth $235,340,000 after purchasing an additional 169,964 shares during the last quarter. Federated Hermes Inc. raised its position in shares of Rhythm Pharmaceuticals by 2.5% in the third quarter. Federated Hermes Inc. now owns 1,727,885 shares of the company’s stock valued at $174,499,000 after buying an additional 41,391 shares during the last quarter. Finally, Westfield Capital Management Co. LP lifted its stake in shares of Rhythm Pharmaceuticals by 21.5% during the second quarter. Westfield Capital Management Co. LP now owns 1,629,468 shares of the company’s stock valued at $102,966,000 after buying an additional 288,376 shares during the period.

Rhythm Pharmaceuticals News Summary

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Analysts at Citizens Jmp raised their price target to $176 and kept a “market outperform” rating, implying a large upside vs. current levels. Article Title
• Positive Sentiment: Guggenheim nudged its target up to $143 with a “buy” rating, another bullish signal from the sell‑side. Article Title
• Positive Sentiment: Q4 results: EPS of ($0.73) beat consensus ($0.79) and revenue of $57.25M topped estimates; revenue rose ~37% year‑over‑year — evidence of commercial traction for IMCIVREE/setmelanotide. Press Release
• Positive Sentiment: Near‑term clinical and regulatory catalysts: PDUFA goal date for the sNDA in acquired hypothalamic obesity is March 20, 2026, and topline Phase 3/Phase 2 readouts (EMANATE and Japanese cohort) are due in March — binary events that could materially re‑rate the stock. Company Release
• Neutral Sentiment: Full Q4 earnings call transcript and coverage are available for investors wanting color on commercial uptake, launch plans and upcoming milestones. Earnings Transcript
• Negative Sentiment: Needham reduced its price target (from $148 to $139) despite keeping a “buy” rating — mixed analyst signals can create short‑term selling pressure. Ticker Report
• Negative Sentiment: Management flagged significantly higher 2026 non‑GAAP operating expenses ($385M–$415M) as HO launch preparations accelerate — investors may view this as margin dilution and a cash‑burn risk ahead of broader commercialization. Seeking Alpha
• Negative Sentiment: Company still shows a negative net margin and very negative ROE — structural profitability concerns remain until revenue scales and launch economics improve. MarketBeat

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.